Tech Company Financing Transactions
Protalix BioTherapeutics Funding Round
Protalix BioTherapeutics, based in Carmiel, received $43.7 million in investment from Alrov, Highbridge Capital Management and More Investment House.
Transaction Overview
Company Name
Announced On
3/13/2020
Transaction Type
Venture Equity
Amount
$43,700,000
Round
Undisclosed
Investors
Proceeds Purpose
Net proceeds from the financing will be used to advance the Company's clinical programs and commercialization of PRX-102 for the treatment of Fabry disease, as well as to further develop its early stage pipeline of therapeutics, and for general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 Snunit St. Science Park POB 455
Carmiel, 2161401
Israel
Carmiel, 2161401
Israel
Phone
Website
Email Address
Overview
Protalix is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by our proprietary ProCellEx plant cell-based protein expression system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dror Bashan
Chief Financial Officer
Eyal Rubin
Chief Medical Officer
Raul Chertkoff
VP - Bus. Development
William Taylor
VP - Engineering
Moshe Chechik
VP - Human Resources
Dafna Shelly
VP - Operations
Yaron Naos
VP - Product Management
Einat Brill-Almon
VP - Product Management
Ronen Rosenberg
VP - Regulatory Affairs
Michal Kahana
Browse more venture capital transactions:
Prev: 3/13/2020: Superpeer venture capital transaction
Next: 3/13/2020: Remesh venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs